Pharmacological activation of tumor suppressor, wild-type p53 as a promising strategy to fight cancer

被引:0
|
作者
Sznarkowska, Alicja [1 ]
Olszewski, Robert [1 ]
Zawacka-Pankau, Joanna [1 ]
机构
[1] Uniwersytetu Gdanskiego Gdanskiego Uniwersytetu M, Miedzyuczelniany Wydzial Biotechnol, Pracownia Diagnost Mol, Katedra Biotechnol, PL-80822 Gdansk, Poland
关键词
p53 tumor suppressor protein; MDM2; p53-HDM2; complex; proteasomal degradation; apoptosis; antitumor therapy; low molecular weight compounds; IN-VIVO; P53-DEPENDENT APOPTOSIS; PHOTODYNAMIC THERAPY; ANTICANCER THERAPY; MDM2; INHIBITORS; DNA-DAMAGE; CELL-DEATH; PROTEIN; PATHWAY; INTERACTS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
A powerful tumor suppressor - p53 protein is a transcription factor which plays a critical role in eliciting cellular responses to a variety of stress signals, including DNA damage, hypoxia and aberrant proliferative signals, such as oncogene activation. Since its discovery thirty one years ago, p53 has been connected to tumorigenesis as it accumulates in the transformed tumor cells. Cellular stress induces stabilization of p53 and promotes, depending on the stress level, cell cycle arrest or apoptosis in the irreversibly damaged cells. The p53 protein is found inactive in more than 50% of human tumors either by enhanced proteasomal degradation or due to the inactivating point mutations in its gene. Numerous data indicate that low molecular weight compounds, identified by molecular modeling or in the functional, cell-based assays, efficiently activate non-mutated p53 in cancer cells which in consequence leads to their elimination due to p53-dependent apoptosis. In this work we describe the structure and cellular function of p53 as well as the latest discoveries on the compounds with high anti-tumor activities aiming at reactivation of the tumor suppressor function of p53.
引用
收藏
页码:396 / 407
页数:12
相关论文
共 50 条
  • [41] Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53
    Sugrue, MM
    Shin, DY
    Lee, SW
    Aaronson, SA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (18) : 9648 - 9653
  • [42] p53/Lactate dehydrogenase A axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild-type p53
    Zhou, Yao
    Niu, Weihong
    Luo, Yanwei
    Li, Hui
    Xie, Yong
    Wang, Heran
    Liu, Yukun
    Fan, Songqing
    Li, Zheng
    Xiong, Wei
    Li, Xiaoling
    Ren, Caiping
    Tan, Ming
    Li, Guiyuan
    Zhou, Ming
    CANCER SCIENCE, 2019, 110 (03) : 939 - 949
  • [43] WILD-TYPE P53 ACTIVATES TRANSCRIPTION INVITRO
    FARMER, G
    BARGONETTI, J
    ZHU, H
    FRIEDMAN, P
    PRYWES, R
    PRIVES, C
    NATURE, 1992, 358 (6381) : 83 - 86
  • [44] Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer
    Bouvet, M
    Bold, RJ
    Lee, J
    Evans, DB
    Abbruzzese, JL
    Chiao, PJ
    McConkey, DJ
    Chandra, J
    Chada, S
    Fang, BL
    Roth, JA
    ANNALS OF SURGICAL ONCOLOGY, 1998, 5 (08) : 681 - 688
  • [45] Adenoviral-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer
    Bouvet, M
    Bold, RJ
    Fang, B
    Evans, DB
    Abbruzzese, JL
    Chiao, PJ
    Chandra, J
    McConkey, DJ
    Roth, JA
    CANCER GENE THERAPY, 1997, 4 (06) : P26 - P26
  • [46] Pharmacological Activation of p53 in Cancer Cells
    Athar, Mohammad
    Elmets, Craig A.
    Kopelovich, Levy
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (06) : 631 - 639
  • [47] Cancer Chemoprevention by Resveratrol: The p53 Tumor Suppressor Protein as a Promising Molecular Target
    Ferraz da Costa, Danielly C.
    Fialho, Eliane
    Silva, Jerson L.
    MOLECULES, 2017, 22 (06):
  • [48] MODULATION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR EXPRESSION BY THE WILD-TYPE AND MUTATED P53 TUMOR-SUPPRESSOR GENE
    WANG, SW
    BOYD, DD
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1995, 7 (01) : 143 - 146
  • [49] Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia
    Folkerts, Hendrik
    Hilgendorf, Susan
    Wierenga, Albertus T. J.
    Jaques, Jennifer
    Mulder, Andre B.
    Coffer, Paul J.
    Schuringa, Jan Jacob
    Vellenga, Edo
    CELL DEATH & DISEASE, 2017, 8 : e2927 - e2927
  • [50] Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia
    Hendrik Folkerts
    Susan Hilgendorf
    Albertus T J Wierenga
    Jennifer Jaques
    André B Mulder
    Paul J Coffer
    Jan Jacob Schuringa
    Edo Vellenga
    Cell Death & Disease, 2017, 8 : e2927 - e2927